It is with deep sadness that we announce our dear friend and colleague Torsten Goesch passed away unexpectedly earlier this week. Torsten was a highly respected member of the Rosetta team and he is much missed. Our thoughts and condolences go out to Torsten's family during this difficult time.
Biotech
Inivata’s InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Inivata was acquired by NeoGenomics in 2021 for $390 million.
Location
Cambridge, UK
History
Acquired by NeoGenomics in 2021 for $390 million
Registered in England No. 3941653 | VAT No. GB 765 3567 96
© 2017 Rosetta Capital Limited | Authorised and regulated by the Financial Conduct Authority
